Artelo Biosciences, Inc. (ARTL)

NASDAQ: ARTL · IEX Real-Time Price · USD
0.334
0.006 (1.86%)
At close: May 25, 2022 4:00 PM
0.341
0.007 (1.977%)
After-hours:May 25, 2022 7:32 PM EDT

Company Description

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system.

Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD.

Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017.

Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Artelo Biosciences, Inc.
Artelo Biosciences Logo
CountryUnited States
Founded2011
IndustryPharmaceuticals
SectorHealth Care
Employees4

Contact Details

Address:
505 Lomas Santa Fe
Solana Beach, CA 92075
United States
Phone858 925 7049
Websiteartelobio.com

Stock Details

Ticker SymbolARTL
ExchangeNASDAQ
Fiscal YearSeptember - August
Reporting CurrencyUS Dollars
CIK Code1621221

Key Executives

NamePosition
Gregory D. Gorgas M.B.A.President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Director
Dr. Andrew Yates Ph.D.Senior Vice President and Chief Scientific Officer
Dr. Steven D. ReichChief Medical Officer
Jason H. BaybuttSenior Vice President of Finance

Latest SEC Filings

DateTypeTitle
May 12, 202210-QQuarterly report [Sections 13 or 15(d)]
Apr 7, 2022S-8Securities to be offered to employees in employee benefit plans
Mar 21, 202210-KTTransition reports [Rule 13a-10 or 15d-10]
Mar 16, 20228-KCurrent report
Mar 9, 20228-KCurrent report
Feb 23, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Feb 9, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Feb 4, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Jan 12, 202210-QQuarterly report [Sections 13 or 15(d)]
Dec 7, 20218-KCurrent report
View All SEC Filings